SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+19.76%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$489M
AUM Growth
+$489M
(+2.1%)
Cap. Flow
-$56.8M
Cap. Flow
% of AUM
-11.63%
Top 10 Holdings %
Top 10 Hldgs %
54.97%
Holding
83
New
12
Increased
18
Reduced
24
Closed
22
Top Buys
| 1 |
CG Oncology
CGON
|
$14.1M |
| 2 |
Scholar Rock
SRRK
|
$12.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$11.4M |
| 4 |
Vaxcyte
PCVX
|
$9.36M |
| 5 |
UroGen Pharma
URGN
|
$8.79M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$17.7M |
| 2 |
Nuvalent
NUVL
|
$15.5M |
| 3 |
Disc Medicine
IRON
|
$11.7M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$8.49M |
| 5 |
Wave Life Sciences
WVE
|
$8.49M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Communication Services | 0% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $39M | 7.2% | 741,972 -69,049 | -9% | -$3.63M |
|
2
Akero Therapeutics
AKRO
$3.74B
| $38.1M | 7.02% | 713,811 -6,181 | -0.9% | -$330K |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $33.9M | 6.25% | 358,297 -187,575 | -34% | -$17.7M |
|
|
4
UroGen Pharma
URGN
$900M
| $27.7M | 5.11% | 2,022,482 +641,324 | +46% | +$8.79M |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $25.3M | 4.67% | 400,772 +63,167 | +19% | +$3.99M |
|
6
Insmed
INSM
$28.8B
| $25.1M | 4.62% | 249,060 -72,306 | -22% | -$7.28M |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $20.7M | 3.82% | 1,832,171 +133,187 | +8% | +$1.51M |
|
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $20.5M | 3.78% | 162,969 +90,386 | +125% | +$11.4M |
|
9
89bio
ETNB
$1.34B
| $20M | 3.69% | 2,037,087 +526,589 | +35% | +$5.17M |
|
10
Oric Pharmaceuticals
ORIC
$994M
| $18.3M | 3.37% | 1,800,829 -259,411 | -13% | -$2.63M |
|
|
11
Nuvalent
NUVL
$5.52B
| $18M | 3.31% | 235,583 -203,435 | -46% | -$15.5M |
|
12
Soleno Therapeutics
SLNO
$3.6B
| $17.1M | 3.16% | 204,591 +38,174 | +23% | +$3.2M |
|
13
Ascendis Pharma
ASND
$11.8B
| $14.9M | 2.75% | 86,552 +10,801 | +14% | +$1.86M |
|
|
14
CG Oncology
CGON
$2.04B
| $14.1M | 2.59% | +541,034 | New | +$14.1M |
|
15
Veracyte
VCYT
$2.39B
| $12.1M | 2.24% | 448,495 -185,337 | -29% | -$5.01M |
|
|
16
Scholar Rock
SRRK
$3.14B
| $12.1M | 2.23% | +341,010 | New | +$12.1M |
|
17
Avidity Biosciences
RNA
$5.99B
| $11.6M | 2.15% | 410,000 -1,312 | -0.3% | -$37.3K |
|
|
18
Vaxcyte
PCVX
$4B
| $9.36M | 1.73% | +287,796 | New | +$9.36M |
|
19
Pfizer
PFE
$141B
| $8.35M | 1.54% | +344,338 | New | +$8.35M |
|
|
BBOT
20
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $6.51M | 1.2% | 613,393 | – | – |
|
21
Gossamer Bio
GOSS
$562M
| $6.33M | 1.17% | 5,146,782 -1,173,902 | -19% | -$1.44M |
|
|
MTSR
22
Metsera, Inc. Common Stock
MTSR
$3.71B
| $5.91M | 1.09% | 207,581 +94,822 | +84% | +$2.7M |
|
23
Elutia
ELUT
$96.7M
| $5.47M | 1.01% | 2,761,684 +91,628 | +3% | +$181K |
|
24
Compugen
CGEN
$132M
| $5.4M | 1% | 3,033,879 +138,449 | +5% | +$246K |
|
25
TELA Bio
TELA
$70.5M
| $5.39M | 0.99% | 2,779,795 +8,507 | +0.3% | +$16.5K |
|